Figure 6.

Systemic administration of sigma-2 receptor ligand slows tumor growth and improves survival. Mice with established pancreas tumors were treated with 5 days of WC26 in one of two dose ranges (2 mg/day, n = 9; Dash line or 1 mg/day n = 10; dashed line) or vehicle control (20% DMSO n = 10; solid line). (A): Mice treated with WC26 had smaller tumors compared to animals vehicle control (p < 0.0001). The two treatment groups were not statistically different. The double-headed arrow denotes the treatment period (5 days). (B): Survival of mice treated with WC26 compared favorably to the mice treated vehicle control (p= 0.002). Survival endpoints were defined as tumor diameter >15 mm or tumor ulceration.